Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
119,747,899
-
Total 13F shares
-
85,675,311
-
Share change
-
-6,186,333
-
Total reported value
-
$162,782,120
-
Price per share
-
$1.90
-
Number of holders
-
103
-
Value change
-
-$11,317,612
-
Number of buys
-
40
-
Number of sells
-
47
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q3 2025
As of 30 Sep 2025,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
103 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
85,675,311 shares.
The largest 10 holders included
BML Capital Management, LLC, Vivo Capital, LLC, VANGUARD GROUP INC, BlackRock, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., Rock Springs Capital Management LP, MORGAN STANLEY, Decheng Capital LLC, GEODE CAPITAL MANAGEMENT, LLC, and D. E. Shaw & Co., Inc..
This page lists
103
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.